Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity
- PMID: 16130178
- DOI: 10.1002/psc.710
Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity
Abstract
Arginine vasopressin (AVP) mediates a wide variety of biological actions by acting on three distinct G-protein coupled receptors, termed V(1a) (vascular), V(1b) (pituitary) and V(2) (renal). It also binds to the oxytocin (OT) receptor. As part of a program aimed at the design of selective agonists for the human V(1b) receptor, we recently reported the human V(1b), V(1a), V(2) and OT receptor affinities of the following position 4 substituted analogues of [deamino-Cys(1)] arginine vasopressin (dAVP)-(1) d[Leu(4)]AVP, (2) d[Orn(4)]AVP, (3) d[Lys(4)]AVP, (4) d[Har(4)]AVP, (5) d[Arg(4)]AVP, (6) d[Val(4)]AVP, (7) d[Ala(4)]AVP, (8) d[Abu(4)]AVP, (9) d[Nva(4)]AVP, (10) d[Nle(4)]AVP, (11) d[Ile(4)]AVP, (12) d[Phe(4)]AVP, (13) d[Asn(4)]AVP, (14) d[Thr(4)]AVP: (15) d[Dap(4)]AVP. With the exception of Nos. 7 and 12, all peptides exhibit very high affinities for the human V(1b) receptor. Furthermore, peptides 1-4 exhibit high selectivities for the human V(1b) receptor with respect to the V(1a), V(2) and OT receptors and, with d[Cha(4)]AVP, in functional tests, are the first high affinity selective agonists for the human V(1b) receptor (Cheng LL et al., J. Med. Chem. 47: 2375-2388, 2004). We report here the pharmacological properties of peptides 1-4, 5 (from a resynthesis), 7, 9-13, 15 in rat bioassays (antidiuretic, vasopressor and oxytocic) (in vitro: no Mg(++)) with those previously reported for peptides 5, 6, 8, 14. We also report the rat V(1b), V(1a), V(2) and OT receptor affinities of peptides 1-5 and the rat V(2) receptor affinities for peptides: 7-15.The antidiuretic activities in units/mg of peptides 1-15, are: 1=378; 2=260; 3=35; 4=505; 5=748; 6=1150; 7=841; 8=1020; 9=877; 10=1141; 11=819, 12=110; 13=996; 14=758; 15=1053. Peptides 1-4 exhibit respectively the following rat and human (in brackets) V(2) receptor affinities: 1=3.1 nm (245 nm); 2=3.4 nm (1125 nm); 3=24.6 nm (11,170 nm); 4=0.6 nm (1386 nm). Their rat V(1b) receptor affinities are 1=0.02 nm; 2=0.45 nm; 3=9.8 nm; 4=0.32 nm. Their rat V(1a) receptor affinities are 1=1252 nm; 2=900 nm; 3=1478 nm; 4=32 nm. Their rat oxytocin (OT) receptor affinities are 1=481 nm; 2=997 nm; 3=5042 nm; 4=2996 nm. All four peptides have high affinities and selectivities for the rat V(1b) receptor with respect to the rat V(1a) and OT receptors. However, in contrast to their high selectivity for the human V(1b) receptor with respect to the human V(2) receptor, they are not selective for the V(1b) receptor with respect to the V(2) receptor in the rat. These findings confirm previous observations of profound species differences between the rat and human V(2) receptors. Peptides 1-4 are promising leads to the design of the first high affinity selective agonists for the rat V(1b) receptor.
Copyright (c) 2005 European Peptide Society and John Wiley & Sons, Ltd.
Similar articles
-
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.J Med Chem. 2004 Apr 22;47(9):2375-88. doi: 10.1021/jm030611c. J Med Chem. 2004. PMID: 15084136
-
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.J Med Chem. 2007 Feb 22;50(4):835-47. doi: 10.1021/jm060928n. J Med Chem. 2007. PMID: 17300166
-
An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.J Pept Sci. 1999 Mar;5(3):141-53. doi: 10.1002/(SICI)1099-1387(199903)5:3<141::AID-PSC180>3.0.CO;2-6. J Pept Sci. 1999. PMID: 10323558
-
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Prog Brain Res. 2008. PMID: 18655903 Review.
-
The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.J Neuroendocrinol. 2004 Apr;16(4):356-61. doi: 10.1111/j.0953-8194.2004.01163.x. J Neuroendocrinol. 2004. PMID: 15089974 Review.
Cited by
-
Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.Br J Pharmacol. 2013 Sep;170(2):278-92. doi: 10.1111/bph.12249. Br J Pharmacol. 2013. PMID: 23725319 Free PMC article.
-
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.J Neuroendocrinol. 2012 Apr;24(4):609-28. doi: 10.1111/j.1365-2826.2012.02303.x. J Neuroendocrinol. 2012. PMID: 22375852 Free PMC article. Review.
-
Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.Peptides. 2011 Aug;32(8):1685-99. doi: 10.1016/j.peptides.2011.06.017. Epub 2011 Jun 28. Peptides. 2011. PMID: 21729729 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous